Page 162 - WSAVA2018
P. 162

A. da Cunha1
1Louisiana State University, Veterinary Clinical Sciences, Baton Rouge- LA, USA
Anderson Favaro da Cunha, DVM, MS, Dipl.ACVAA
Professor and Chief, Veterinary Anesthesia and Analgesia
Department of Veterinary Clinical Sciences
School of Veterinary Medicine, Louisiana State University
Baton Rouge, Louisiana, USA
Non-client-owned, shelter animals often require sedation, anesthesia and analgesia for orchiectomy (neuter) or ovariohysterectomy (spay) prior to adoption. The Association of Shelter Veterinarians published a guideline regarding the anesthesia of shelter animals with emphasis on patient care and welfare including anesthesia, analgesia and postoperative care.
There are also several websites elucidating ways to preserve and protect the animal rights at shelters. They are:;; www.; and www.
Many studies show that the anesthesia-related mortality rate is reduced with in depth understanding of patient’s history and pre-op examinations. However, when animals present for surgeries in shelters, they usually lack that important clinical history, performing full blood work
for all animals prior to surgery is cost prohibitive and most of feral animals do not allow the veterinarian to approach for a complete physical exam prior to drug injection. Therefore, the anesthesia-related mortality rate in shelters is higher. However, there are several simple techniques that can be used for the anesthesia management of feral and shelter animals in order to improve their survival rate.
1-The most important techniques you can add to your practice in order to increase survival rates in face of lack of pre-op clinical information are: 1- vital signs monitoring during anesthesia; 2- personnel training to recognize any possible cardiovascular and respiratory complication;
3- readiness for aggressive treatments of possible complications.
2-Before the beginning of your anesthesia management, it is important to provide a stress free environment. Stress leads to catecholamine release and arrhythmias
25-28 September, 2018 | Singapore
1. Olivry T, DeBoer DJ, Griffin CE, Halliwell RE, Hill PB, Hillier A, et al. The ACVD Task Force on Canine Atopic Dermatitis: forewords and lexicon. Veterinary Immu- nology and Immunopathology 2001;81: 143-6
2. Willemse T. Atopic skin disease: a review and a reconsideration of diagnostic criteria: Journal of Small Animal Practice 1986;27: 771-8.
3. Hanifin JM, Rajka G. Diagnostic features of atopic dermatitis. Acta Derma- to-Venereologica 1980;92(Suppl.): 44-7.
4. Prélaud P, Guaguère E, Alhaidari Z, Faivre N et al. Réévaluation des critères de diagnostic de la dermite atopique [Reevaluation of diagnostic criteria of atop- ic dermatitis]. Revue De Médecine Vétérinaire 1998;149: 1057-64.
diagnosis. Veterinary Dermatology 2010;21: 20-4.
6. Picco F, Zini F, Net C, Naegeli C, Bigler B, Rüfenacht S, et al. A prospective study on canine atopic dermatitis and food-induced allergic dermatitis in Switzer- land. Veterinary Dermatology 2008;19: 150-5.
7. Duangkaew L, Larsuprom L, Annukkul P, Lekcharoensuk C, Chen C, et al. A field trial in Thailand of the efficacy of oral fluralaner for the treatment of dogs with generalized demodicosis. Veterinary Dermatology 2018;29 doi: 10.1111/vde. 12524.
8. Beugnet F, deVos C, Liebenberg J, Halos L and Fourie J. Afoxolaner against fleas: immediate efficacy and resultant mortality after short exposure on dogs. Parasite 2014;21: 42.
9. Becskei C, De Bock F, Illambas J Cherni JA, Fourie JJ, Lane M, et al. Efficacy and safety of a novel isoxazoline, sarolaner (SImparicaTM), for the treatment of sarcoptic mange in dogs. Veterinary Parasitology 2016;222: 56-61.
10. Cavalleri D, Murphy M, Seewald W, Drake J, Nanchen S. Assessment of the speed of kill of flea kill of lotilaner (CredelioTM) throughout the month following oral administration. Parasites and Vectors 2017;10: 529.
11. Olivry T, Deboer DJ, Favrot C, Jackson HA, Mueller RS, Nuttall T, et al. Treatment of canine atopic dermatitis: 2010 clinical practice guidelines from the International Task Force on Canine Atopic Dermatitis. Veterinary Dermatology 2010;21: 233-48.
12. Zur G, Gurevich B and Elad D. Prior antimicrobial use as a risk factor for resistance in selected Staphylococcus pseudintermedius isolates from the skin and ears of dogs. Veterinary Dermatology 2016;27: 468-e125.
13. Hensel N, Zabel S and Hensel P. Prior antibacterial drug exposure in dogs with methicillin-resistant Staphylococcus pseudintermedius (MRSP) pyoderma. Veterinary Dermatology 2016;27: 72-e20.
14. Carlotti DN. Cutaneous manifestations of food hypersensitivity. In: Noli C, Foster A and Rosenkrantz, ed. Veterinary Allergy. West Sussex: Wiley-Blackwell, 2014; 108-14.
15. DeBoer DJ. Guidelines for symptomatic medical treatment of canine atopic dermatitis. In: Noli C, Foster A and Rosenkrantz, ed. Veterinary Allergy. West Sussex: Wiley-Blackwell, 2014; 108-14.

   160   161   162   163   164